臨床外科78巻1号

2023年01月発行

特集 外科医が知っておくべき！ 免疫チェックポイント阻害薬 各論

胃癌に対する免疫チェックポイント阻害療法の臨床試験と将来展望

著者： 田中浩明¹

所属機関： ¹大阪公立大学消化器外科学

ページ範囲：P.36 - P.41

【ポイント】
◆保険適用となっているニボルマブとペムブロリズマブそれぞれの適用，レジメン，また免疫チェックポイント阻害薬（ICIs）の有害事象について単剤および化学療法との併用による影響などを解説する．
◆結果が期待される現在進行中の第Ⅲ相臨床試験（術前術後補助療法，マルチキナーゼ阻害薬との併用の試験）について解説する．
◆将来のICIsの位置づけとして，ほかのICIsやHER2陽性胃癌に対するICIの使用，クローディン抗体との併用に関する臨床試験について解説する．

参考文献

1）Kang YK, Boku N, Satoh T, et al：Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens（ONO-4538-12, ATTRACTION-2）：a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390（10111）：2461-2471, 2017

2）Kang YK, Chen LT, Ryu MH, et al：Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer（ATTRACTION-4）：a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 23：234-247, 2022

3）Janjigian YY, Shitara K, Moehler M, et al：First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma（CheckMate 649）：a randomised, open-label, phase 3 trial. Lancet 398（10294）：27-40, 2021

4）Shitara K, Van Cutsem E, Bang YJ, et al：Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer：the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 6：1571-1580, 2020

5）Shitara K, Özgüroğlu M, Bang Y-J, et al：Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer（KEYNOTE-061）：a randomised, open-label, controlled, phase 3 trial. Lancet 392（10142）：123-133, 2018

6）Fuchs CS, Doi T, Jang RW, et al：Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer：phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4：e180013, 2018

7）Boku N, Satoh T, Ryu MH, et al：Nivolumab in previously treated advanced gastric cancer（ATTRACTION-2）：3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer 24：946-958, 2021

8）Marabelle A, Le DT, Ascierto PA, et al：Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer：results from the phase Ⅱ KEYNOTE-158 study. J Clin Oncol 38：1-10, 2020

9）Janjigian YY, Bendell J, Calvo E, et al：CheckMate-032 study：efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 36：2836-2844, 2018

10）Bang YJ, Ruiz EY, Van Cutsem E, et al：Phase Ⅲ, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer：primary analysis of JAVELIN Gastric 300. Ann Oncol 29：2052-2060, 2018

11）Oaknin A, Gilbert L, Tinker AV, et al：Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high（dMMR/MSI-H）or proficient/stable（mmrp/mss）endometrial cancer：interim results from GARNET-a phase Ⅰ, single-arm study. J Immunother Cancer 10：e003777, 2022

12）Janjigian YY, Maron SB, Chatila WK, et al：First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer：an open-label, single-arm, phase 2 trial. Lancet Oncol 21：821-831, 2020

13）Janjigian YY, Kawazoe A, Yanez P, et al：The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600（7890）：727-730, 2021

14）Hellmann MD, Paz-Ares L, Bernabe Caro R, et al：Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381：2020-2031, 2019

15）Larkin J, Chiarion-Sileni V, Gonzalez R, et al：Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381：1535-1546, 2019

16）Fukuoka S, Hara H, Takahashi N, et al：Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer：an open-label, dose-escalation, and dose-expansion phase Ⅰb trial（REGONIVO, EPOC1603）. J Clin Oncol 38：2053-2061, 2020

17）Kawazoe A, Fukuoka S, Nakamura Y, et al：Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting（EPOC1706）：an open-label, single-arm, phase 2 trial. Lancet Oncology 21：1057-1065, 2020